Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Gelber

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2025
Why Adjuvant Treatment With a CDK4/6 Inhibitor Should Be Recommended for Women With High-Risk Breast Cancer: Methodologic Considerations on Available EvidenceFabio Conforti, Federico Merlo, Laura Pala, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2003
American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant settingEric P Winer, Clifford Hudis, Harold J Burstein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 2004
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004Eric P Winer, Clifford Hudis, Harold J Burstein, et al.
European Journal of Cancer (Oxford, England : 1990)|January 15, 2023
Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancerPaolo Nuciforo, John Townend, Martine J Piccart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2023
Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast CancerMarion T van Mackelenbergh, Sibylle Loibl, Michael Untch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2023
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 TherapyPierre Squifflet, Everardo D Saad, Sibylle Loibl, et al.
The Lancet. Oncology|November 27, 2025
Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trialsFabio Conforti, Johannes Holtschmidt, Valentina Nekljudova, et al.
JAMA|January 30, 2025
Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer: The ALEXANDRA/IMpassion030 Randomized Clinical TrialMichail Ignatiadis, Andrew Bailey, Heather McArthur, et al.
The Lancet. Oncology|May 10, 2025
Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort studyEva Blondeaux, Amir Sonnenblick, Elisa Agostinetto, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2025
Why Adjuvant Treatment With a CDK4/6 Inhibitor Should Be Recommended for Women With High-Risk Breast Cancer: Methodologic Considerations on Available EvidenceFabio Conforti, Federico Merlo, Laura Pala, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2003
American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant settingEric P Winer, Clifford Hudis, Harold J Burstein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 2004
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004Eric P Winer, Clifford Hudis, Harold J Burstein, et al.
European Journal of Cancer (Oxford, England : 1990)|January 15, 2023
Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancerPaolo Nuciforo, John Townend, Martine J Piccart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2023
Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast CancerMarion T van Mackelenbergh, Sibylle Loibl, Michael Untch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2023
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 TherapyPierre Squifflet, Everardo D Saad, Sibylle Loibl, et al.
The Lancet. Oncology|November 27, 2025
Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trialsFabio Conforti, Johannes Holtschmidt, Valentina Nekljudova, et al.
JAMA|January 30, 2025
Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer: The ALEXANDRA/IMpassion030 Randomized Clinical TrialMichail Ignatiadis, Andrew Bailey, Heather McArthur, et al.
The Lancet. Oncology|May 10, 2025
Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort studyEva Blondeaux, Amir Sonnenblick, Elisa Agostinetto, et al.
Pageof 2